
Sign up to save your podcasts
Or


Surprisingly (unbelievably?) impressive RCT evaluating the Blys/APRIL inhibitor "telitacicept" for patients with SLE (mixed SLE and SLE-LN). Very curious to see where the FDA goes with this one.
Paper: https://www.nejm.org/doi/full/10.1056/NEJMoa2414719
By Michael Putman4.9
114114 ratings
Surprisingly (unbelievably?) impressive RCT evaluating the Blys/APRIL inhibitor "telitacicept" for patients with SLE (mixed SLE and SLE-LN). Very curious to see where the FDA goes with this one.
Paper: https://www.nejm.org/doi/full/10.1056/NEJMoa2414719

498 Listeners

298 Listeners

125 Listeners

3,347 Listeners

1,145 Listeners

119 Listeners

195 Listeners

515 Listeners

69 Listeners

4 Listeners

370 Listeners

182 Listeners

185 Listeners

20 Listeners

7 Listeners